2023
DOI: 10.1002/jmv.29036
|View full text |Cite
|
Sign up to set email alerts
|

Long‐term SARS‐CoV‐2 neutralizing antibody level prediction using multimodal deep learning: A prospective cohort study on longitudinal data in Wuhan, China

Cong Fang,
Weiming Yan,
Yuying Chen
et al.

Abstract: The ongoing epidemic of SARS‐CoV‐2 is taking a substantial financial and health toll on people worldwide. Assessing the level and duration of SARS‐CoV‐2 neutralizing antibody (Nab) would provide key information for government to make sound healthcare policies. Assessed at 3‐, 6‐, 12‐, and 18‐month postdischarge, we described the temporal change of IgG levels in 450 individuals with moderate to critical COVID‐19 infection. Moreover, a data imputation framework combined with a novel deep learning model was imple… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 47 publications
0
1
0
Order By: Relevance
“…Current Long COVID treatment regimens are based on small pilot studies and still need further validation of effectiveness from larger clinical studies ( Davis et al, 2023 ), therefore their effectiveness is still under debate. Furthermore, the neutralizing antibodies produced during the initial infection decline over time and thus cannot effectively prevent the occurrence of subsequent infections, leading to common re-infections ( Fang et al, 2023 ), which further increase the overall mortality rate and risk of Long COVID. Thus, there is an urgent need for measures to prevent re-infection ( Boufidou et al, 2023 ).…”
Section: Introductionmentioning
confidence: 99%
“…Current Long COVID treatment regimens are based on small pilot studies and still need further validation of effectiveness from larger clinical studies ( Davis et al, 2023 ), therefore their effectiveness is still under debate. Furthermore, the neutralizing antibodies produced during the initial infection decline over time and thus cannot effectively prevent the occurrence of subsequent infections, leading to common re-infections ( Fang et al, 2023 ), which further increase the overall mortality rate and risk of Long COVID. Thus, there is an urgent need for measures to prevent re-infection ( Boufidou et al, 2023 ).…”
Section: Introductionmentioning
confidence: 99%